Monday, 29th May 2017 18:58:23 GMT+0530
Ad Here

ARCHIVES

Funding from DBT has boosted the joint efforts of Sphaera Pharma, LeadInvent Technologies, and ICGEB to develop a novel combination therapy for the treatment of resistant and non-responsive cancers. Please visit this URL for more details - http://biospectrumindia.ciol.com/content/BioSpecial/11211088.asp
Sphaera Pharma to Present at the 31st Annual J.P. Morgan Healthcare Conference Corporate Overview to be presented on Wednesday, January 9th at 11:00 am Pacific Time at the 31st Annual Conference in San Francisco, California as part of the Emerging Markets – Asia Track   JP Morgan Global Healthcare Conference 2013 Sphaera Pharma today announced it will present at the 31st Annual JP Morgan Healthcare Conference in San Francisco. Sphaera’s President and Chief Executive Officer, Sundeep Dugar, Ph.D., will provide an overview of the company and its scientific programs on Wednesday, January 9, 2013 at 11:00 am in the Emerging Markets – Asia Track.   About Sphaera Pharma Sphaera Pharma is an integrated drug discovery and development organization led by pharma and biotech professionals with global experience. A presence in Singapore, the U.S. and India, affords us access to capital efficient resources and global expertise in a unique drug discovery and development model. We are bridging innovation, resources and expertise to bring innovative therapies to patients with unmet medical needs. Sphaera is discovering and developing a balanced portfolio of discovery projects and clinical programs that address important disease areas, including: oncology, metabolic disorders, and infectious disease.
It is with deep regret that we announce the passing of Dr Krishnamurthy Narayanasamy, Executive VP on feb 22, 2013. Dr Narayanasamy has been an integral part of sphaera for last 3 years. He will be dearly missed as a great scientist, colleague and a friend. We hold him and his family in our thoughts and prayers. The vacuum created with his loss can never be filled. Have our sincere condolences.
Sphaera Pharma completes phase I trials for neuropathic pain drug. Please visit this URL for more details - http://www.pharmabiz.com/NewsDetails.aspx?aid=77194&sid=1
Sphaera Pharma presented a poster on their Neuropathic Pain program at The 2013 Pain and Migraine Therapeutics Summit held in San Diego, CA on November 7-8, 2013. The poster summarized the novel synergistic combination of two APIs to treat painful diabetic peripheral polyneuropathy (DPN) in humans. This project was done in collaboration with Synthia Dermatech. Sphaera Pharma and Synthia Dermatech are looking to partner this program for rapid commercialization towards a topical based application for the treatment of neuropathic pain. If you are interested in a copy of the poster presented, select this poster link to request a copy.

Recent News